Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no
known cure. Recent years have seen rapid advances in our understanding of the molecular …

Persistent challenges in managing pulmonary vascular disease progression and poor
outcomes, despite the aggressive use of current drug therapies, highlight the need for …

An improved understanding of the molecular causes and modifiers of pulmonary arterial
hypertension (PAH) has emerged during the last several decades. However, the survival of …

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with a relentless
course toward heart failure and early death. Existing PAH therapies, all of which were …

The management of pulmonary arterial hypertension (PAH) has significantly evolved over
the last decades in the wake of more sensitive diagnostics and specialized clinical programs …

Pulmonary arterial hypertension (PAH) is a rare yet serious progressive disorder that is
currently incurable. This female-predominant disease unfolds as a pan-vasculopathy that …

The pathobiology of pulmonary arterial hypertension (PAH) is complex and incompletely
understood. Although three pathogenic pathways have been relatively well characterised, it …

Pulmonary arterial hypertension (PAH), at one time a largely overlooked disease, is now the
subject of intense study in many academic and biotech groups. The availability of new …

Pulmonary arterial hypertension (PAH) is a rare disease of the pulmonary vasculature
characterised by progressive remodelling and narrowing of the pulmonary arteries due to …

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …